A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs VAY 736 (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 22 Feb 2017 Status changed from discontinued to completed.
- 14 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2014 Planned End Date changed from 1 Oct 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.